Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation

類似資料

• Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses
  著者:: Brinkmann, Christel Rothe, 等
  出版事項: (2018)
• Immune checkpoints and the HIV-1 reservoir: proceed with caution
  著者:: Olesen, Rikke, 等
  出版事項: (2016)
• Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation
  著者:: Rasmussen, Thomas Aagaard, 等
  出版事項: (2013)
• The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
  著者:: Søgaard, Ole S., 等
  出版事項: (2015)
• HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal
  著者:: Wu, Guoxin, 等
  出版事項: (2017)